SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Biogen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 8, 2022 - (NASDAQ: BIIB)

NEW YORK, Feb. 23, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice on behalf of shareholders of Biogen Inc..

Shareholders who purchased shares of BIIB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/biogen-inc-loss-submission-form-2/?id=23926&from=4

CLASS PERIOD: June 7, 2021 to January 11, 2022

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: 1) there was a significant, undisclosed lobbying campaign between Biogen and the Food and Drug Administration ("FDA") that was instrumental in the decision to file and approve Aduhelm, a drug being developed to treat Alzheimer's disease; 2) the Phase III ENGAGE study demonstrated that Aduhelm failed to achieve a clinical benefit to Alzheimer's patients; 3) ENGAGE was a failed study from which Biogen concluded not to seek FDA approval for Aduhelm in 2019; and 4) defendants misled investors as to the way in which approval was achieved, that the clinical data did not support a clinical benefit by taking Aduhelm and that side-effects were dangerous and serious.

DEADLINE: April 8, 2022 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/biogen-inc-loss-submission-form-2/?id=23926&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of BIIB during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 8, 2022. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903

Cision View original content:https://www.prnewswire.com/news-releases/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-biogen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-april-8-2022--nasdaq-biib-301487493.html

SOURCE The Gross Law Firm